Disrupting DDR Signaling by Targeting Leptin-Dependent NRP-1/ OBR with NOV2 to Overcome Resistance & Induce Chromosomal Instability
• See how Theranovir are developed NOV2, a monoclonal antibody targeting the Leptin-dependent NRP-1/OBR complex involved in DDR signaling and nuclear translocation
• Sharing preclinical data demonstrating NOV2’s ability to induce chromosomal instability, including centromere disruption and telomere shortening
• Exploring NOV2’s potential to overcome resistance and relapse, and its future use in combination with PARP inhibitors